Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002028280 | SCV002283475 | uncertain significance | Multiple endocrine neoplasia, type 2 | 2021-03-07 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with lysine at codon 134 of the RET protein (p.Glu134Lys). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with RET-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV004671603 | SCV005157009 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-03-23 | criteria provided, single submitter | clinical testing | The p.E134K variant (also known as c.400G>A), located in coding exon 3 of the RET gene, results from a G to A substitution at nucleotide position 400. The glutamic acid at codon 134 is replaced by lysine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear. |